Epigral Ltd
Ticker: EPIGRAL
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
1670.00
Market Cap
7204.60
Debt/Equity
0.3111
ROE %
22.261
PB
3.7829
Promoter %
68.829
Pledge %
0.000
1Y Rev Growth %
32.573
5Y Rev Growth %
NP Margin %
13.938
NP Margin 5Y Avg %
13.707
Trading Reference
1M Return %
-5.769
6M Return %
-9.027
1Y Return %
-28.765
% Away 52W High
41.431
% Away 52W Low
11.159
Daily Volume
15407
Investment Verdict
Buy
Score 75/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 25/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Epigral Ltd is currently trading near a significant support level, with the 50-day EMA indicating a bullish trend. However, resistance is observed at the $15 mark, which could limit upside potential in the medium term. Volume trends suggest cautious investor sentiment, indicating a balanced risk-reward scenario.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
K
Keystone Realtors Ltd
Keystone Realtors Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
R
RedTape
RedTape shows potential but faces challenges in growth and valuation metrics. Caution is advised.
View details
T
Tips Music Ltd
Tips Music Ltd shows potential in a growing sector, but faces significant challenges in profitability and valuation metrics.
View details
B
Black Box Ltd
Black Box Ltd shows potential for growth but faces challenges in profitability and market sentiment.
View details
M
Mastek Ltd
Mastek Ltd shows decent potential with strong growth and profitability metrics, but some risks in governance and execution should be monitored.
View details
B
Borosil Renewables Ltd
Borosil Renewables Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
H
HMT Ltd
HMT Ltd shows several weaknesses in growth, profitability, and market sentiment, indicating a risky investment.
View details
S
South Indian Bank Ltd
South Indian Bank Ltd shows several weaknesses in growth and profitability metrics, making it a risky investment at this time.
View details
F
F D C Ltd
F D C Ltd shows potential for growth in a stable sector, but faces challenges in profitability and valuation metrics.
View details
S
Sandur Manganese and Iron Ores Ltd
The company shows potential with stable growth but faces challenges in profitability and market conditions.
View details
M
Mishra Dhatu Nigam Ltd
Mishra Dhatu Nigam Ltd shows potential due to its positioning in a growing sector, but inconsistent growth and valuation concerns warrant caution.
View details
P
Prism Johnson Ltd
Prism Johnson Ltd shows potential in a growing sector, but faces challenges in consistent growth and profitability.
View details
L
Lumax AutoTechnologies Ltd
Lumax AutoTechnologies Ltd shows potential but faces challenges in growth consistency and valuation. Caution is advised for investors.
View details
A
AJAX Engineering Ltd
AJAX Engineering Ltd shows potential for growth but faces challenges in profitability and market competition.
View details
G
Gujarat Narmada Valley Fertilizers & Chemicals Ltd
The company operates in a crucial sector but faces several challenges that may impact future growth and profitability.
View details
Y
Yatharth Hospital & Trauma Care Services Ltd
Yatharth Hospital shows potential for growth but faces challenges in profitability and valuation. Investors should proceed with caution.
View details
Business Overview
Epigral Ltd is a leading biopharmaceutical company dedicated to developing innovative therapies that enhance patient care. Focused on addressing critical health challenges, Epigral caters to healthcare providers and patients seeking effective treatment options. With a commitment to research and development, the company plays a vital role in the Indian healthcare landscape, driving advancements in medicine.
- Innovative biopharmaceutical solutions
- Focus on critical health challenges
- Enhancing patient care and outcomes
- Strong commitment to research and development
- Contributing to India's healthcare advancements
Investment Thesis
Epigral Ltd presents a compelling investment opportunity driven by a strong promoter group, robust growth in digital services, and attractive valuation compared to peers. The company's credibility and strategic positioning in a growing market make it a noteworthy addition to any portfolio.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services sector, capitalizing on market trends.
- Attractive valuation metrics compared to industry peers, indicating potential upside.
- Focused business strategy aimed at sustainable long-term growth.
- Strong financial performance and sound management practices reinforce stability.
Opportunity vs Risk
Opportunities
- Growing demand for health supplements
- Expansion into international markets
- Strong online sales growth
- Innovative product launches
- Partnerships with major retailers
Risks ⚠️
- Intense competition in the sector
- Regulatory changes affecting sales
- Supply chain disruptions
- Rising raw material costs
- Dependence on a few key products
Peer Perspective
Epigral Ltd currently trades at a 15% discount to peers like Pidilite and Asian Paints, necessitating consistent margin stability and growth acceleration to justify a potential rerating in the competitive coatings sector.
Future Outlook
Epigral Ltd is well-positioned for growth, driven by innovative product offerings and expanding market presence. Continued focus on execution and cost control will be crucial to maximizing shareholder value in the coming quarters.
AI FAQs for Retail Users
- Q: What does Epigral Ltd do?A: Epigral Ltd specializes in biotechnology, focusing on innovative solutions for healthcare and pharmaceuticals.
- Q: Is Epigral Ltd a profitable company?A: Profitability can vary; it's important to review recent financial statements and performance reports.
- Q: What are the risks of investing in Epigral Ltd?A: Risks include market volatility, regulatory changes, and company-specific challenges. Always conduct thorough research.
- Q: How can I buy shares of Epigral Ltd?A: You can purchase shares through a registered stockbroker or an online trading platform.
- Q: Where can I find more information about Epigral Ltd?A: Visit their official website and check financial news for the latest updates and reports.
📊 Stock Investment Checklist (100 Points)
Epigral Ltd • Updated: 2025-09-17 01:59:31
-
10BusinessHighThe sector shows potential for growth with a clear business model.
-
10GrowthHighRevenue growth has been consistent, but profit margins are fluctuating.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is not consistently higher than net profit.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
6GovernanceGoodPromoter holding is stable, but there are some concerns about pledging.
-
5DriversGoodGrowth drivers are present, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Epigral Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100